Aaron Tallent

Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.

Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.

Oncology leaders testified before a House subcommittee about how drug shortages are hindering cancer care in the US and threatening the lives of patients.

Women are underrepresented in clinical trials of NSCLC treatment, a meta-analysis suggests.

Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.